Abstract. Sobokchukeo-Tang (ST) is a well-known formula that is used for treating primary dysmenorrhea caused by blood stasis syndrome (BSS) in Korea and China. The current study investigated the anti-inflammatory and anti-adipogenesis effects of ST on adipocytes and macrophages. The anti-inflammatory efficacy of ST was evaluated in RAW 264.7 cells and differentiated THP-1 cells. To induce inflammation, the cells were treated with lipopolysaccharide (LPS; 1 µg/ml). Following the induction of inflammation, the levels of proinflammatory cytokines, interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) in the cell supernatant were detected using enzyme-linked immunosorbent assay. 3T3-L1 preadipocytes differentiated into adipocytes in response to insulin, isobutyl-1-methylxanthine and dexamethasone (MDI). To confirm the anti-adipogenesis efficacy of ST, we investigated Oil Red O staining was performed, triglyceride (TG) and leptin secretion were measured, and the protein expression of lipid metabolism-associated factors was determined. ST significantly inhibited TNF-α and IL-6 production in the LPS-treated RAW 264.7 cells compared with LPS stimulation alone. In addition, the concentrations of IL-6 and TNF-α were significantly inhibited by ST in LPS-treated THP-1 cells. Lipid accumulation was reduced by ST, similarly to the positive control treatment, SB203580. In the ST-treated group, the TG and leptin concentrations were inhibited by up to 50 and 83%, respectively, compared with MDI induction only. The ST-treated group reduced the protein expression of peroxisome proliferator-activated receptor-γ and CCAAT/enhancer-binding protein α compared with MDI induction only. The results of the present study demonstrated that ST exerts anti-inflammatory effects on LPS-treated mouse and human macrophage cell lines. ST inhibited adipogenesis in MDI-induced 3T3-L1 adipocytes, as indicated by the significant reduction in TG and leptin concentrations without cytotoxicity. Thus, ST may be useful as a therapeutic agent for preventing lipid-associated diseases, including obesity and atherosclerosis.
Introduction
Blood stasis syndrome (BSS) is an interesting research area in studies of traditional Asian and Western medicine (1) focused on vascular disease. In Korean Traditional Medicine (KTM), BSS is considered to be caused by blood circulation and Qi circulatory disturbances, which are the result of accidents, surgery and stress (2) . Clinically, BSS is characterized by pain, bleeding and coagulation, in the vasculature and the muscles. It is diagnosed based on increased viscosity of the blood, red blood cell (RBC) deformability, and the acceleration of RBC maturation, platelet aggregation and microcirculatory dysfunction (3) . Recently, various studies have reported that BSS is important in metabolic diseases (MDs) (4), including obesity, atherosclerosis and cardiovascular disease (5) . Previous studies have demonstrated that MDs are closely associated with inflammation in vascular diseases (6, 7) .
Sobokchukeo-Tang (ST) is a well-known formula that is used for treating primary dysmenorrhea caused by BSS in Korea and China. ST is used to treat BSS, including uterine myoma, primary dysmenorrhea and chronic pelvic inflammation (8) . Other reports have described the efficacy of ST for treating vascular disorders and pain (9) , endometriosis (10), cancer (11) and menstrual irregularities in vivo (12) .
It is established that the levels of tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) are increased in MD patients (13) . Lipid diseases, including obesity and atherosclerosis, are associated with the elevated concentration of inflammatory markers, including C-reactive protein and proinflammatory cytokines, including interleukin-1β (IL-1β), IL-6 and TNF-α (14) (15) (16) . Peroxisome proliferator-activated receptors (PPARs) are ligand-dependent transcription factors that regulate lipid and glucose metabolism (17) . PPARs predominantly include three subtypes; δ, β and γ. The major role of PPAR-γ in adipocytes is the regulation of adipogenesis and lipid homeostasis, whereas PPAR-δ is expressed in hepatocytes, enterocytes and the renal proximal tubule cells of the kidney. Despite research into PPAR-α and PPAR-γ, the molecular function of PPAR-β remains unclear. However, PPAR-β is expressed in many regions of tissues and cells, with relatively high levels present in the brain, adipose tissue and skin (18) . The CCAAT/enhancer-binding protein (C/EBP) family also serves an important role in modulating adipocytes (19) . These adipogenic transcriptional factors modulate lipid production in the immune system.
The present study observed the anti-inflammatory effects of ST extracts on macrophage cell lines. The anti-adipogenesis efficacy of ST on mouse fibroblast cell lines was also investigated. The results demonstrated that ST modulated adipokine expression under inflammatory conditions.
Materials and methods
Preparation of the herbal formula. Each of the 10 herbal components of ST were mixed as listed in Table I . All herbal components were purchased from Omniherb (Deagu, Korea) in 2012. The origins of each herb were confirmed by Dr Jun-Kyung Lee of Hyemin Dispensary of Oriental Medicine (Jeonju, Korea). A voucher specimen (BS-6) was deposited at the KM fundamental Research Division, Korea Institute of Oriental Medicine (Daejeon, Korea). The extracts were prepared in our laboratory from a mixture of chopped crude herbs. Extraction was performed using distilled water at 100˚C for 3 h by reflux extraction, using the extractor COSMOS-660 (Kyungseo Machine Co., Incheon, Korea). The solution was filtered through filter paper. The extract was freeze-dried to create a powder (extraction yield, 13.04%). The prepared powder was stored at -70˚C.
High performance liquid chromatography (HPLC) analysis.
The lyophilized extract (10 mg) was dissolved in 70% methanol (5 ml) and then filtered through a 0.2 µm membrane filter (Woongki Science Co., Ltd., Seoul, Korea) before being injected into HPLC for component analysis. The purity of the ten standard compounds was ≥98.0% using HPLC analysis. The HPLC-grade solvents, methanol, acetonitrile and water were obtained from J.T. Baker (Phillipsburg, NJ, USA). Trifluoroacetic acid (analytical reagent grade) and the standards were procured from Sigma-Aldrich (Merck Millipore, Darmstadt, Germany).
The HPLC system consisted of a Waters Alliance 2695 system coupled with a 2998 photodiode array detector (Waters Corporation, Mitford, MA, USA). Data processing was performed with Empower software, version 3 (Waters Corporation). The 10 components in ST were separated using a Luna 5 µm C18 100A column (4.6x250 mm, 5 µm particle size, no. 00G-4252-E0; Phenomenex, Inc., Torrance, CA, USA). The monitoring was performed at 230 nm for three compounds (1, albiflorin; 2, paeoniflorin; and 3, benzoic acid), 280 nm for five compounds (4, gallic acid; 5, coumarin; 6, cinnamic acid; 7, cinnamic aldehyde; and 8,6-gingerol) and 320 nm for two compounds [9, nodakenin; and 10, ferulic acid (10) ]. The mobile phases consisted of water with 0.1% (v/v) trifluoroacetic acid (solvent A) and acetonitrile (solvent B) at a flow rate of 1.0 ml/min. The gradient conditions changed as presented in Table II . The injection volume was 10 µl.
Cell culture and cytotoxicity. The RAW 264.7 murine macrophage cell line, the 3T3-L1 mouse embryonic fibroblast cell line and the THP-1 human acute monocytic leukemia cell line were obtained from the American Type Culture Collection (ATCC; Manassas, VA, USA). The RAW 264.7 [5.5% fetal bovine serum (FBS, Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) and 1% penicillin/streptomycin (P/S)] and 3T3-L1 (10% calf serum and 1% P/S) cells were cultured in Dulbecco's modified Eagle's medium (DMEM; Gibco; Thermo Fisher Scientific, Inc.). The THP-1 cells were cultured in RPMI-1640 medium (Gibco; Thermo Fisher Scientific, Inc.; 10% FBS, 1% P&S). The culture flask was maintained at 37˚C in a humidified atmosphere consisting of 5% CO 2 and 95% air.
The cell cytotoxicity was detected by using Cell Counting Kit-8 (CCK-8; Dojindo Molecular Technologies, Inc., Kumamoto, Japan). Briefly, the RAW 264.7, 3T3-L1 and THP-1 cells were seeded at 3x10 3 , 8x10 2 and 1x10 4 cells/well in 96-well plates. After incubation overnight, the cells were treated with 0-1,000 µg/ml ST for 24 h. CCK-8 solution (10 µl) was added to each well. After 4 h, the absorbance was measured at 450 nm using a Benchmark Plus microplate reader (Bio-Rad Laboratories, Inc., Hercules, CA, USA), and the percentages of the control (without ST) were calculated.
Anti-inflammatory activity. To confirm the levels of cytokines in the RAW 264.7 cells, the cells were cultured with 5x10 4 cells per well in 48-well plates with lipopolysaccharide (LPS; Escherichia coli 0111:B4; Sigma-Aldrich, Merck Millipore; 1 µg/ml) for 24 h to induce inflammation. The cells were treated with ST extract (62.5-500 µg/ml). The IL-6 (cat. no. DY406) and TNF-α (cat. no. DY410) concentration in the supernatant was analyzed using ELISA (R&D Systems, Inc., Minneapolis, MN, USA).
THP-1 cells were cultured at 1x10 6 cells/well in 6-well plates in the presence of phorbol 12-myristate 13-acetate (20 ng/ml; Sigma-Aldrich; Merck Millipore) for 24 h to induce differentiation into macrophage-like cells. Differentiated cells were then incubated with serum-free medium for 1 day at 37˚C and 5% CO 2 . Cells were treated with LPS (1 µg/ml) in RPMI medium (10% FBS and 1% P/S) in the presence or absence of ST extracts (62.5-500 µg/ml). The cells were incubated for 24 h, then the supernatant was taken to measure the concentration of proinflammatory cytokines [IL-1β (cat. no. KHC0014), IL-6 (cat. no. KHC0061C) and TNF-α (cat. no. KHC3014C); Invitrogen; Thermo Fisher Scientific, Inc.].
3T3-L1 cell culture and differentiation.
To induce adipocyte differentiation, the 3T3-L1 cells were cultures in 6-well plates at 3x10 5 cells/well to confluence. After 2 days, the cells were treated with a differentiation mixture containing 1 µM dexamethasone, 5 mM 3-isobutyl-1-methylxanthine and 1 µg/ml insulin (Sigma-Aldrich; Merck Millipore) in DMEM with 10% FBS (MDI) to induce the preadipocytes to differentiate. After 2 days, the medium was replaced with DMEM with 10% FBS and 1 µM insulin. Cultures were incubated for 2 days, after which the culture medium was replaced again with DMEM (10% FBS) and repeated at 2 day intervals until day 7. SB203580, a p38 mitogen-activated protein kinase (MAPK) inhibitor (Cell Signaling Technologies, Inc., Danvers, MA, USA) was used as the positive control. The triglyceride (TG; BioAssay Systems, Hayward, CA, USA; cat. no. ETGA-200) was detected by colorimetric method in the cell lysates at 570 nm using a microplate reader (Benchmark Plus; Bio-Rad Laboratories, Inc.). The leptin (R&D Systems, Inc.; cat. no. MOB00) concentrations were measured by ELISA in supernatant at 450 nm using a microplate reader.
Oil Red O (ORO) staining. MDI-induced differentiated 3T3-L1 cells were treated with ST at concentrations of 62.5, 125, 250 and 500 µg/ml. The fat droplets were visualized using ORO staining. The cells were fixed with 10% formalin for 1 h, washed with 60% isopropanol, and dried. Then, the cells were stained with 0.5% ORO solution in 60% isopropanol for 10 min and then washed four times with distilled water. The images of the stained cells were acquired using an inverted contrast phase microscope (Olympus Corporation, Tokyo, Japan). To detect the absorbance of the sample, the stained cells were dissolved in DMSO and absorbance was measured at 570 nm by a microplate reader.
Anti-adipogenesis activity. The TG and leptin production was measured on day 7 after differentiation. The cells were washed three times with PBS and scraped in 500 µl 5% Triton X-100. The cell lysate was centrifuge at 848 x g for 3 min at 4˚C to remove the fat layers. The supernatant was assayed for TG production, according to the manufacturer's protocol (BioAssay Systems; cat. no. ETGA-200). The supernatant in the differentiated 3T3-L1 cells treated with ST were used to determine the leptin concentration according to the manufacturer's protocol (R&D Systems, Inc.; cat. no. MOB00).
Protein expression. Cells were treated with ST (62.5, 125, 250 and 500 µg/ml) for 5 days and then washed twice with ice-cold PBS. The cell lysates were prepared with radioimmunoprecipitation cell lysis buffer (GenDEPOT, Barker, TX, USA). The lysates were centrifuged at 15,928 x g for 15 min at 4˚C. The concentration of protein was measured using the Bicinchoninic Acid Protein Assay kit (Thermo Fisher Scientific, Inc.). A total of 30 µg of each protein was separated by electrophoresis using 4-20% Criterion™ TGX™ precast gels (Bio-Rad Laboratories, Inc.) and transferred onto polyvinylidene fluoride membranes (GE Healthcare Life Sciences, Chalfont, UK). The membranes were blocked with 5% skim milk and incubated with primary antibodies (1:1,000 dilutions; β-actin (cat. no. sc-81178), PPAR-γ (cat. no. sc-7273), C/EBPα (cat. no. sc-61); Santa Cruz Biotechnology, Inc., Dallas, Texas. USA) overnight at 4˚C. The next day, the membranes were incubated with goat anti-rabbit secondary antibodies (1:5,000; cat. no. 170-6515; Bio-Rad Laboratories, Inc.) for 1 h at room temperature, and immunoreactive proteins were detected using an enhanced chemiluminescence assay kit (Thermo Fisher Scientific, Inc.). Bands were detected using a ChemiDoc™ XRS + image analyzer (Bio-Rad Laboratories, Inc.).
Statistical analysis. Data are presented as the mean ± standard error and were analyzed by analysis of variance and the Bonferroni multiple comparison method using Systat 13.0 (Fig. 1A) . Fig. 1B presents the chromatograms of the ST extract solutions.
Anti-inflammatory activity. There was no cytotoxicity up to 1,000 µg/ml ST (data not shown). The cytokine concentrations were detected in the supernatants of LPS-treated RAW 264.7 cells and THP-1 cells. The inflammatory efficacy was examined using mouse and human cell lines. ST significantly inhibited the production of TNF-α by up to 57% in LPS-treated RAW 264.7 mouse cells compared with cells treated with LPS only (P<0.01; Fig. 2A) . The IL-6 concentration in the LPS-treated group (11.87±1.95 ng/ml) exhibited a significant increase of ~72-fold compared with the control group (0.16±0.076 ng/ml; P<0.0001) and IL-6 was significantly reduced by ST (500 µg/ml) by 59-65% compared with LPS treatment (P=0.008; Fig. 2B ).
Cytokine levels were also measured in human THP-1 cells. The LPS-treated group exhibited significantly increased concentrations of IL-1β (12.79±1.61 ng/ml; P<0.0001), IL-6 (8.58±1.21 ng/ml; P<0.0001) and TNF-α (69.95±0.75 ng/ml; P<0.0001) compared with the control. The ST (500 µg/ml) treatment reduced the IL-1β (4.11±0.32 ng/ml), IL-6 (4.79±0.30 ng/ml) and TNF-α (36.70±13.31 ng/ml) released concentrations compared with LPS-only treatment (P<0.01; Fig. 3) . Thus, the data confirmed that ST suppressed IL-6 and Lipid accumulation in adipocytes. 3T3-L1 cells were incubated in MDI-differentiation medium in the presence or absence of ST extracts. SB203580 treatment was the positive control, and basal growth medium treatment was the negative control. Lipid accumulation was observed by ORO staining on day 7. The retained dye by the fat droplets was dissolved with DMSO and measured at a wavelength of 570 nm by microplate reader. The fat droplets were increased by MDI-differentiation medium. When SB203580 was administered in the MDI-induced well as a positive control, the fat droplets were inhibited by up to 72%. In the ST treatment group, it was observed that the fat droplets were reduced by ST in a dose-dependent manner ( Fig. 4A and B) . This suggested that the ST treatment inhibited lipid accumulation and adipogenesis in a dose dependent manner.
Intracellular lipid regulation.
The intracellular TG and leptin content was quantified at 7 days post-differentiation of the preadipocytes. The TG content was significantly increased in the cells cultured with MDI by 4-fold (142.74±4.14 µM) compared with the control group (33.18±0.89 µM; P<0.0001). The positive control, SB203580, significantly inhibited TG production in MDI-induced cells compared with MDI treatment alone (P=0.003). The ST-treated group suppressed the TG production by up to 50% compared with MDI treatment only (Fig. 5A) .
When 3T3-L1 cells were treated with MDI, the leptin content increased to 156.64±9.50 pg/ml. In the positive control, the leptin content was significantly inhibited by ~78% (34.42±1.93 pg/ml; P<0.01; Fig. 5B) , and in the ST-treated group, the leptin concentration was significantly inhibited by up to 95% (P<0.01). Thus, ST suppressed the release of TG and leptin from adipocytes.
Protein expression in adipogenesis. The cell protein levels of PPAR-γ and C/EBPα were determined. Differentiated cells were treated with various concentrations of ST for 5 days, and the protein levels of PPAR-γ and C/EBPα were determined by western blotting. As demonstrated in Fig. 5C , SB203580 suppressed PPAR-γ and C/EBPα expression compared with differentiated cells treated with MDI only. The ST-treated groups exhibited reduced PPAR-γ and C/EBPα protein levels in a dose-dependent manner. These results indicated that ST inhibits 3T3-L1 pre-adipocyte differentiation partially through PPAR-γ and C/EBPα via p38 MAPK signaling.
Discussion
BSS is a blood circulation disorder. Various diseases, including hyperviscosity, ischemic brain injury, microvascular accidents, atherosclerosis, hypertension and pain, are caused by BSS, which can be explained by the inflammatory vascular pathology (20) . The traditional herbal formula, ST, is used for the treatment of BSS, pain, cancer and menstrual irregularities. The current study confirmed the efficacy of the anti-inflammatory activity of ST by using adipocytes and macrophages.
Obesity-associated inflammation is suspected to contribute to various diseases, including cancer, cardiovascular disease and diabetes. The proinflammatory cytokines/chemokines, including IL-1β, IL-6, TNF-α, adipokines and leptin, are important for the initiation and development of MDs (21) . The present study investigated whether ST modulates the proinflammatory cytokines, IL-6 and TNF-α, and confirmed the cytokine releasing levels in mouse and human macrophage cell lines. ST inhibited the release of proinflammatory cytokines compared with the levels in LPS-treated cells. ST may improve pain and cancer by inhibiting pro-inflammatory activity.
Obesity causes chronic inflammatory reactions associated with pro-inflammatory cytokines (IL-1β, IL-6 and TNF-α) and adipokines. Numerous studies have indicated that adipocytes produce considerable concentrations of IL-1β, IL-6 and TNF-α (22) (23) (24) (25) . There is a tendency for differentiated adipocytes to undergo apoptosis, followed by macrophage infiltration of the developed adipocytes. Adipose tissue from obese subjects has a higher concentration of secreted cytokines, including IL-1β, IL-6, IL-8 and TNF-α (26) . Adipose tissue significantly contributes to the production of cytokines. TNF-α is a positively associated with adipocyte size and plasma adipokine levels (27) . The current study demonstrated that IL-6 and TNF-α release is inhibited by ST in a concentration-dependent manner in LPS-treated RAW 264.7 cells and differentiated THP-1 cells, thus, providing another association between fat tissue and inflammation in obesity. Additionally, ST inhibited the production of TG and leptin in 3T3-L1 cells.
Adipocytes are a storage tissue for overnutrition, and it is recognized that adipocytes release numerous factors that regulate inflammation and metabolism. The mechanisms resulting in macrophage development to adipose tissue are currently under investigation. Increased concentrations and release of cytokines and chemokines has been implicated in this process (28) . We hypothesize that the reduction in TG accumulation and leptin release following ST treatment is partially mediated by reduced fatty acid synthesis. Leptin serves a crucial role in the endocrine system regarding obesity; it stimulates appetite suppression and regulates energy consumption (29) . It is well known that the blood concentration of leptin is closely associated with the TG concentration. The amount of adipose tissue is dependent on circumstances and hormones, including insulin and gonadotropins (30) . In the current study, ST inhibited the TG and leptin levels in MDI-induced differentiated 3T3-L1 cells. In addition, ST inhibited adipocyte differentiation and lipid droplet formation.
The expression of the adipogenic markers, PPAR-γ and C/EBPα, were inhibited by ST treatment during adipogenesis of MDI-induced. SB203580 (p38 MAPK inhibitor) was used as a positive control. The role of p38MAPK in adipocyte differentiation remains a controversial topic. p38 activation is altered by MDI-differentiation of 3T3-L1 (31) and suppression of p38 early in MDI-differentiation of 3T3-L1 cells was demonstrated to decrease adipocyte development (32) . In the current study, treatment with ST inhibited the PPAR-γ and C/EBPα expression, which suggested that ST may suppress adipocyte differentiation partially by inhibiting p38 MAPK. It was also observed that SB203580 inhibited PPAR-γ and C/EBPα expression. adipocytes. At day 5, protein was isolated from adipocytes and the protein expression levels of PPAR-γ and C/EBPα were determined by western blot analysis. T The data are presented as the mean ± standard error of three independent experiments. ## P<0.01 vs. cont; * P<0.05, ** P<0.01 vs. MDI. MDI, 1 µM dexamethasone, 5 mM 3-isobutyl-1-methylxanthine and 1 µg/ml insulin; SB, SB203580; ST, Sobokchukeo-Tang; PPAR-γ, peroxisome proliferator-activated receptor-γ; C/EBPα, CCAAT/enhancer-binding protein α.
In conclusion, the results of the current study demonstrated that ST has anti-inflammatory efficacy in LPS-treated macrophages and inhibits adipogenesis in MDI-induced 3T3-L1 adipocytes, as indicated by the significant reduction in TG and leptin accumulation without any cytotoxicity. Furthermore, the suppressive effects of ST are potentially mediated by the downregulated expression of adipogenesis-associated genes. Thus, ST may act as a therapeutic agent to prevent lipid-associated diseases, including obesity and atherosclerosis.
